Microbot Medical granted critical patent in China by CNIPA

Microbot Medical (MBOT) announced that it has been granted a critical patent in China by the China National Intellectual Property Administration, CNIPA, a key step in the Company’s global IP expansion strategy. The patent, which covers the robotic manipulation of a surgical tool handle, further validates the Company’s technological innovation and expands its intellectual property portfolio. This milestone demonstrates Microbot’s continued commitment to protect its proprietary technology as it builds a broader global commercialization strategy.